Vector & Plasmid (AAV & pDNA) — Design → GMP, without detours

Scope: AAV design & manufacturing (capsid/promoter/payload), plasmid DNA (research → GMP), production in adherent, suspension, or fixed-bed systems; chromatography-based empty/full control; phase-appropriate analytics; fill–finish.

At MycoVista, vectors and plasmids aren’t an add-on—they’re a core competency. We design the genetic architecture, the production process, and the documentary spine as one system. The result: vector lots that behave, pDNA that reads clean, and artifacts that stand up in inspection. Manufacturability by default.

Why teams choose MycoVista for vectors & pDNA

Decisive. Technical. Audit-ready. That’s our operating system.

• End-to-end ownership. Vector design → plasmid supply → upstream (adherent/suspension/fixed-bed) → downstream (capture/polish/empty–full) → analytics → fill–finish—harmonized across a unified digital QMS (ALCOA+) in two synchronized facilities.
• Single narrative, many modalities. AAV and plasmids share one control strategy, tuned per program so your CMC reads like a coherent story.
• Evidence over optimism. We tie each claim to a method, an acceptance criterion, and traceable data. If it won’t scale or pass inspection, it doesn’t ship.
• Design that respects operations. Headroom over hero runs; closed processing where it pays; geometry and cleaning that survive 3 a.m. shifts.

What “Vector & Plasmid” means at MycoVista

• AAV design & build. Capsid selection or engineering brief; promoter/terminator and regulatory elements; payload sizing and manufacturability heuristics; off-target risk thinking from day one.
• AAV manufacturing. Adherent, suspension, or fixed-bed production; triple-plasmid or producer-line strategies; perfusion options where quality or throughput win.
• Plasmid DNA supply. Research through GMP pDNA with topology (supercoiled) safeguarded and endotoxin controlled; built for your vector process (transfection or producer lines).
• Downstream reality. Chromatography-forward capture/polish; charge-based empty/full tuning; TFF-centric buffer exchange; solvent/detergent compatibility where warranted.
• Analytics that convince. vg titer (qPCR/ddPCR), capsid quantitation, empty/full profiling, residuals (DNA/protein/nuclease/detergents), sterility & mycoplasma, potency.
• Fill–finish. Vector-appropriate buffers, osmolality control, sterile filtration feasibility, and presentation (vial/syringe) tied to stability truths.

AAV by design: from capsid to control strategy

You don’t pick a capsid; you pick a control strategy. We start there.

1) Architecture & payload

• Capsid brief. Tropism and pre-existing immunity context; manufacturability signals (yield, empty rate, polishing behavior).
• Expression cassette. Promoter/enhancer choice, intron/UTR design, polyA selection—balanced to payload size and potency goals.
• Payload sizing. Overpack risk flagged early; truncation/defect risk assessed; packaging limits respected.

2) Production approach

• Adherent vs suspension vs fixed-bed. Chosen by scale, facility fit, and quality targets; closed processing wherever it buys risk reduction.
• Transfection vs producer line. Triple-plasmid for agility; producer cell lines when consistency and cost win at scale.
• Perfusion options. Where residence time, productivity, or quality demand; validated for cleaning and operator reality.

3) Empty/full strategy

• Primary capture sized for load & recovery; polishing tuned to capsid surface charge; gradients or step-elutions built for lot-to-lot stability.
• Orthogonality. Charge-based separation paired with an orthogonal confirmation method appropriate to phase (e.g., density-sensitive analytics) to avoid self-deception.

4) Residuals & safety baked in

• Residual host DNA/protein, plasmid remnants, nuclease, detergents— acceptance criteria set early.
• Sterility, endotoxin, mycoplasma aligned to phase and presentation; hold-time and filter-through studies done in development, not the release queue.

Plasmid DNA (pDNA): clarity you can see, topology you can trust

Plasmids are the skeleton key of your vector program. We build them to unlock, not jam.

1) Upstream (E. coli), bank to tank

• Host & selection logic. Antibiotic or antibiotic-free strategies, copy number discipline, and origins that behave under scale-like feed and temperature.
• Fermentation. Carbon-limited fed-batch to avoid overflow metabolism; oxygen transfer planned with real kLa; antifoam compatibility with DSP.
• Banking. Research → master → working banks with identity, purity, viability, and adventitious agent testing where required.

2) Lysis, clarification, and capture

• Alkaline lysis conditioned for viscosity and RNA control; shear budgets respected.
• Clarification by centrifugation and filtration mapped with pressure–throughput curves; flocculation/conditioning only if it pays in validation.
• Capture. AEX-based capture sized to supercoiled content and endotoxin risk; pre-conditioning chemistry validated to avoid resin grief.

3) Polishing & topology control

• Topology distribution (SC/OC/L) measured and protected; polishing that preserves SC while pushing endotoxin and protein down.
• Residuals (RNA, genomic DNA, proteins, salts, detergents) targeted with orthogonal analytics; conductivity and pH windows locked for repeatability.

4) Formulation & presentation

• Buffers that preserve topology and downstream performance (e.g., for transfection);
• Sterile filtration feasibility proven early; hold-time studies that reflect your operations.

Upstream (AAV) — adherent, suspension, fixed-bed

Goal: consistent harvests that make downstream boring—in a good way.

• Seed trains sized to turnaround and contamination risk; bank usage tracked in QMS; matrix differences handled in transfer protocols.
• Transfection tuned for cell health, reagent stoichiometry, and osmolality; media exchanges designed for scale; mixing plans that survive real impellers.
• Fixed-bed programs planned for shear, diffusion, and cleaning realities; perfusion where viable cell density and quality demand it.
• Closed processing for risk and operator safety where it earns its keep; BSL-2 practices where required.

Downstream (AAV & pDNA) — capture, polish, prove

Downstream is where vector and plasmid lots become releasable.

For AAV

• Clarification & nuclease. Harvest conditioning and nuclease steps sized to DNA load and filter life; residual nuclease acceptance criteria defined up front.
• Capture. Modality-appropriate affinity or charge-first strategies sized by breakthrough, pressure, and cleanability; lifecycle cost that doesn’t wreck Q4.
• Polishing. Ion exchange or mixed-mode tuned to impurity maps; empty/full separation with gradients or steps you can run in production—documented, not magical.
• Buffer exchange & concentration. TFF designed to protect potency and avoid aggregation; osmolality and pH windows locked.

For pDNA

• Capture. AEX capture for capacity and selectivity; breakthrough and cleaning ranges set by data.
• Polishing. Steps that protect SC while taking endotoxin down hard; residual RNA and proteins monitored with orthogonal methods.
• UF/DF & formulation. MWCO picked by hydrodynamic radius; diafiltration designed around shear and ionic strength; sterile-filter feasibility declared early.

Analytics & characterization: the assays that run the story

Decisions come from data. We build the stack accordingly.

Vectors (AAV)

• Titer: qPCR/ddPCR with controls to avoid inhibition and bias.
• Capsid: total capsid quantification; identity confirmation.
• Empty/full: charge-based primary with orthogonal confirmation, appropriate to phase.
• Potency: cell-based transduction or function readouts aligned to MoA; reference standards managed.
• Residuals & safety: host DNA/protein, plasmid traces, nuclease/detergents; sterility, endotoxin, mycoplasma; adventitious agents per phase.

Plasmids (pDNA)

• Identity: restriction/enzyme mapping and/or sequence confirmation appropriate to phase.
• Purity: topology (SC/OC/L), residual RNA and genomic DNA, protein, endotoxin.
• Suitability: transfection-relevant readouts where warranted.

Stability & comparability

• Programs for real/accelerated storage, agitation, freeze–thaw;
• Comparability for scale/site/raw-material changes with acceptance windows you can defend.

Fill–finish for vectors & pDNA

• Buffers & excipients chosen by potency retention, osmolality, and sterile filter recovery.
• Sterile filtration feasibility tested early; post-filter activity/titer recovery tracked.
• Aseptic operations in isolator/RABS; vial and prefilled syringe options; labeling & packaging built for cold-chain reality.
• Hold times validated; shipping conditions simulated.

Facilities & scale (selected highlights)

• Production suites: adherent, suspension, and fixed-bed footprints; perfusion options; closed-system capability.
• Cleanrooms: ISO 8/7 with unidirectional flows; BSL-2 implementation where required; validated utilities (HPW/clean steam/compressed air) with trending.
• Chromatography & TFF: pilot to GMP skids; multi-column options; viral filtration where applicable; automated diafiltration recipes with validated sensors.
• Analytics: qPCR/ddPCR, HPLC/UPLC, LC-MS (as needed), CE-SDS, icIEF, DLS/osmolality; sterility, endotoxin, mycoplasma; phase-appropriate tools for empty/full confirmation.
• Data systems: validated CDS, LIMS, ELN; eBMR/eBR; audit trails and access controls aligned to ALCOA+.

cGMP, regulatory, and QMS

• QbD: QTPP → CQAs → CPPs mapped at project start; risk-based DoE locked into protocols.
• Digital QMS (ALCOA+): deviations/CAPA, change control, eBMR/eBR, validated computerized systems—harmonized across San Diego & Montréal with mirrored methods and release packages.
• Regulatory authoring: IND/IMPD/BLA text written from your actual methods and data; reviewer Q&A answered with statistics plans and raw data, not vibes.
• Audit-ready artifacts: method files, validation/qualification, mass balance, recovery, empty/full runs, and lifecycle summaries for resins/filters.

Program Onboarding

Speed is useful only if outputs are inspection-grade. In month one you receive:

1. A phase-appropriate control strategy for AAV and/or pDNA (CQAs, CPPs, acceptance criteria, residuals).
2. A DoE plan for upstream (production/transfection/retention) and downstream (capture/polish/empty–full/TFF) with sampling plans and pass/fail criteria.
3. A Gantt & risk map (FMEA) with decision gates to IND/registration—plus a plasmid supply plan and a fill–finish feasibility outline.

Start: Share indication context, dose & route, target presentation, scale, and stability goals. We return a design space, analytics, unit-op parameters, and a documented path to GMP.

Typical timelines (indicative, biology-gated)

• Design & feasibility: capsid/cassette brief; early production test; capture/polish scout; pDNA feasibility & yield/topology checks.
• Development & lock: upstream DoE (cell, feed, transfection/perfusion), downstream (recovery, impurity clearance, empty/full), analytics stack; process lock when CPPs/CQAs land in range.

• Scale confirmation: engineering runs with mass balance and trending; stability enrollment; documentation pack for regulatory and QA.

Tech transfer & rescue programs

We stabilize mid-flight programs and make the data durable.

• Document triage: methods, deviations, stability, change controls, residuals.
• Gap map: which CQAs/CPPs are truly uncontrolled; fastest safe fixes.
• Stabilize → optimize → re-lock: we don’t ship risk; we reduce it, document it, and gate it.

ESG & supply chain (reliability is a quality attribute)

• Qualified alternates for critical resins, membranes, nucleases, and plastics; stocking plans sized to campaign risk.
• Closed processing and single-use where they cut risk/time; stainless where cleaning validation and cost win.
• Utilities stewardship (gas, water, solvent handling) sized to your route and scale.

Deliverables

• AAV control strategy with unit-ops, acceptance criteria, and empty/full plan.
• pDNA dossier (banking, yield, topology, residuals).
• Process description with design space and CPP limits; validated control loops/interlocks.
• Analytics package (methods; qual/val status; trending); stability protocol and interim data.
• Batch records (eBMR/eBR) tied to sensors and interventions; CMC text ready for IND/IMPD/BLA.

A few patterns that make us different

• Empty/full we can run, not just admire. Separation tuned to lot-to-lot stability and operator reality.
• Topology that travels. pDNA SC content protected from shake-flask to final fill.
• Headroom, not hero runs. Processes survive fouling, filter variability, and night-shift reality.
• One truth, two hubs. The same control strategy follows your program across San Diego & Montréal.

Frequently asked

Do you support both adherent and suspension AAV? Yes—plus fixed-bed and perfusion where they win; we document why.

Can you supply GMP pDNA for our vector runs? Yes—research through GMP with topology and endotoxin controlled, built to your process.

How do you confirm empty/full? Charge-based primary with orthogonal confirmation appropriate to phase; acceptance windows predefined.

Will you transfer our sponsor methods? If fit-for-purpose, yes; where gaps exist, we close and validate.

Can you handle producer cell lines? Yes—when consistency and economics win; we’ll show the validation footprint before committing.

Summary—why MycoVista for vectors & pDNA

Because vectors and plasmids are only “good” when they manufacture and pass. We design capsids, cassettes, processes, and documents as one system, prove sameness when you change, and deliver lots that behave from bench to GMP. The result: Design → Data → Decision, without detours.

MycoVista | San Diego, CA

Start Program Onboarding → Share dose/route, presentation, scale, and stability goals. We’ll return a design space, control strategy, and a documented path to GMP.

EN / FR support available.